Unlock instant, AI-driven research and patent intelligence for your innovation.

Inhibitors of anti-apoptotic proteins

A technology of solvates and compounds, applied in the field of chemical compounds of thiazolidine parts, can solve problems such as safety and incompetence

Inactive Publication Date: 2010-11-24
BURNHAM INST OF MEDICAL RES
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, the potency of these antagonists is not as high as expected
In addition, existing antagonists are characterized by other disadvantages, such as insufficiency or safety concerns

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Inhibitors of anti-apoptotic proteins
  • Inhibitors of anti-apoptotic proteins
  • Inhibitors of anti-apoptotic proteins

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0093] Example 1. Protein expression and purification

[0094] recombinant full-length BCL-X L Generated from pET-19b (Novagen) plasmid construct containing the entire nucleotide sequence of BID fused to an N-terminal poly-His tag. Untagged proteins were expressed in E. coli BL21 in LB medium at 37°C and induced with 1 mM IPTG for a period of 3-4 hours. produce similarly 15 N-labeled protein, whose growth occurs when adding 0.5g / L 15 NH 4 Cl M9 medium. After cell lysis, soluble protein was purified by Hi-Trap chelating column (Amersham, Pharmacia) followed by ion exchange purification by MonoQ (Amersham, Pharmacia) column. Final BID samples were dialyzed against a buffer suitable for subsequent experiments.

Embodiment 2

[0095] Example 2. Molecular Modeling

[0096] Molecular modeling studies were performed using the software package Sybyl version 6.9 (TRIPOS) on several R12000 SGI Octane workstations. The docked structure of the compound was originally obtained by Gold. The molecular models of the compounds were energy minimized with MAXIMN2 (Sybyl). For each molecule, 20 solutions were generated and graded according to Goldscore. Solutions were finally graded by visual observation of linked compounds in deep hydrophobic grooves on the BCL-xL surface. Surface representations are generated by MOLCAD.

Embodiment 3

[0097] Example 3. NMR Spectrum

[0098] For all NMR experiments, BCL-xL was exchanged in 50 mM phosphate buffer, pH 7.5 and measured at 30°C. with 0.5mM 15 N-labeled protein samples to measure 2D of BCL-xL[ 15 N, 1 H]-HSQC spectrum. All experiments were performed with a 600 MHz Bruker Avance spectrometer equipped with either a TXI probe or a TCI cryoprobe. In all experiments, dephasing of the remaining water signal was obtained in the WATERGATE sequence. To examine the ability of test compounds to bind Bcl-xL, 25 μM protein samples were prepared and collected 1D in the absence and presence of test compounds 1 H NMR spectrum. Binding is easily detected in these simple experiments by observing the aliphatic region of the spectrum due to the altered chemical shift of the active-site methyl group of Ile, Leu, Thr, Val or Ala (region between 0.8 and 0.3 ppm ).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Various compounds comprising a thiazolidine ring are described as well as the use of such compounds to inhibit at least one BCL-2 protein family member. One of the compounds described has the structure the structure A, wherein each of R1 and R2 comprises hydrogen, a substituted or unsubstituted straightchained aliphatic group, a halogen, an alkoxyl, a halogen-substituted alkyl, a halogensubstituted alkoxyl, hydroxyl, carboxyl, cyano group, an amido group, a substituted or unsubstituted cycloaliphatic group, a substituted or unsubstituted aromatic group, or a substituted or unsubstituted heterocyclic group; X comprises oxygen, sulfur, or imino group; and Z comprises a moiety such as naphthaline or dehydronaphthaline, among others.

Description

[0001] background field of invention [0002] The present invention relates generally to compounds useful in the treatment of various disorders, diseases and pathological conditions, and more particularly to the use of chemical compounds comprising thiazolidine moieties to treat these disorders. Background technique [0003] The apoptotic cascade in cells is known to cause cell death. When cells overproduce anti-apoptotic proteins, such as BCL-2 family proteins, uncontrolled cell growth may ensue, potentially leading to the development of a variety of serious diseases, disorders and conditions, especially cancer. [0004] Therefore, there is a need to inhibit anti-apoptotic proteins, such as BCL-2 family proteins. A variety of potential BCL-2 antagonists have been identified in the past. However, none of these compounds inhibited all six proteins in the BCL-2 family, i.e., all of the following proteins: BCL-X L , BCL-2, BCL-W, BCL-B, BFL-1, and MCL-1. For example, none o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/535
CPCC07D277/36A61P1/04A61P11/06A61P13/12A61P17/00A61P17/06A61P19/00A61P19/02A61P21/04A61P25/00A61P35/00A61P35/04A61P37/00A61P43/00A61P5/00A61P3/10
Inventor M·派利奇亚
Owner BURNHAM INST OF MEDICAL RES